# A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

> **NCT04142762** · PHASE1 · COMPLETED · sponsor: **Assembly Biosciences** · enrollment: 80 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H2158
- **DRUG:** Itraconazole
- **DRUG:** Rifampin
- **DRUG:** Midazolam
- **DRUG:** Ethinyl Estradiol / Levonorgestrel
- **DRUG:** Esomeprazole
- **DRUG:** Placebo matching oral contraceptive

## Key facts

- **NCT ID:** NCT04142762
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-18
- **Primary completion:** 2020-01-12
- **Final completion:** 2020-01-29
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142762, "A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04142762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*